The Chaperone System in Salivary Glands: Hsp90 Prospects for Differential Diagnosis and Treatment of Malignant Tumors.
Ganetespib
Hsp90
Hsp90 biomarker
Hsp90 pathogenic
chaperone system
differential diagnosis
negative chaperonotherapy
salivary gland tumors
Journal
International journal of molecular sciences
ISSN: 1422-0067
Titre abrégé: Int J Mol Sci
Pays: Switzerland
ID NLM: 101092791
Informations de publication
Date de publication:
18 Aug 2022
18 Aug 2022
Historique:
received:
16
07
2022
revised:
11
08
2022
accepted:
13
08
2022
entrez:
26
8
2022
pubmed:
27
8
2022
medline:
30
8
2022
Statut:
epublish
Résumé
Salivary gland tumors represent a serious medical problem and new tools for differential diagnosis and patient monitoring are needed. Here, we present data and discuss the potential of molecular chaperones as biomarkers and therapeutic targets, focusing on Hsp10 and Hsp90. The salivary glands are key physiological elements but, unfortunately, the information and the means available for the management of their pathologies, including cancer, are scarce. Progress in the study of carcinogenesis has occurred on various fronts lately, one of which has been the identification of the chaperone system (CS) as a physiological system with presence in all cells and tissues (including the salivary glands) that plays a role in tumor-cell biology. The chief components of the CS are the molecular chaperones, some of which belong to families of evolutionarily related molecules named heat shock protein (Hsp). We are quantifying and mapping these molecular chaperones in salivary glands to determine their possible role in the carcinogenetic mechanisms in these glands and to assess their potential as diagnostic biomarkers and therapeutic targets. Here, we report recent findings on Hsp10 and Hsp90 and show that the quantitative and topographic patterns of tissue Hsp90 are distinctive of malignant tumors and differentiate benign from malignant lesions. The Hsp90 results show a correlation between quantity of chaperone and tumor progression, which in turn calls for negative chaperonotherapy, namely, elimination/inhibition of the chaperone to stop the tumor. We found that in vitro, the Hsp90 inhibitor Ganetespib is cytotoxic for the salivary gland UM-HACC-2A cell line. The drug, by interfering with the pro-survival NF-κB pathway, hampers cellular proliferation and migration, and favors apoptosis, and can, therefore, be considered a suitable candidate for future experimentation to develop a treatment for salivary gland tumors.
Identifiants
pubmed: 36012578
pii: ijms23169317
doi: 10.3390/ijms23169317
pmc: PMC9409185
pii:
doi:
Substances chimiques
Antineoplastic Agents
0
HSP90 Heat-Shock Proteins
0
Molecular Chaperones
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Références
Mol Cancer Ther. 2014 Feb;13(2):353-63
pubmed: 24398428
Eur J Histochem. 2013 Jun 28;57(2):e20
pubmed: 23807299
Int J Mol Sci. 2021 Sep 25;22(19):
pubmed: 34638658
J Exp Clin Cancer Res. 2021 May 14;40(1):170
pubmed: 33990203
Anticancer Res. 2003 Mar-Apr;23(2B):1325-31
pubmed: 12820390
Biophys Chem. 2007 Jul;128(2-3):125-39
pubmed: 17442480
Anticancer Res. 2018 Mar;38(3):1551-1562
pubmed: 29491085
Oncotarget. 2017 Jan 17;8(3):3946-3956
pubmed: 27992367
Mol Cancer. 2017 Dec 20;16(1):178
pubmed: 29262861
N Engl J Med. 2005 Oct 6;353(14):1489-501
pubmed: 16207851
Curr Cancer Drug Targets. 2020;20(4):253-270
pubmed: 31793427
Apoptosis. 2017 Mar;22(3):369-380
pubmed: 27878398
J Cell Biochem. 2018 Sep;119(9):7350-7362
pubmed: 29768689
Carcinogenesis. 2004 Apr;25(4):527-33
pubmed: 14688025
Sci Rep. 2017 Feb 20;7:41416
pubmed: 28216675
Mol Biol Cell. 2011 Apr 15;22(8):1167-80
pubmed: 21346199
Blood. 2010 Jul 8;116(1):45-53
pubmed: 20351313
J Med Chem. 2010 Jan 14;53(1):3-17
pubmed: 20055425
J Ultrasound Med. 2020 Jun;39(6):1223-1232
pubmed: 31880357
Biomed Res Int. 2018 Feb 14;2018:4319369
pubmed: 29651431
Cancers (Basel). 2019 Aug 16;11(8):
pubmed: 31426412
Sci Rep. 2018 May 1;8(1):6829
pubmed: 29717218
Oncol Rep. 2021 Feb;45(2):448-458
pubmed: 33416122
Adv Exp Med Biol. 2021;1340:11-73
pubmed: 34569020
Expert Opin Investig Drugs. 2017 Jan;26(1):103-108
pubmed: 27922280
Nature. 2012 Jan 26;483(7387):100-3
pubmed: 22281684
Cancer Res. 2005 Dec 1;65(23):10686-91
pubmed: 16322212
J Physiol Biochem. 2020 May;76(2):279-290
pubmed: 32100243
Endocrine. 2015 Apr;48(3):886-93
pubmed: 25096912
Acta Histochem. 2021 Sep;123(6):151771
pubmed: 34419757
Mol Carcinog. 2015 Oct;54(10):1147-58
pubmed: 24861206
Mol Cell. 2002 Feb;9(2):401-10
pubmed: 11864612
Onco Targets Ther. 2020 Apr 08;13:2997-3011
pubmed: 32308431
BMC Cancer. 2013 Mar 25;13:152
pubmed: 23530663
Oncogene. 2004 Jul 8;23(31):5378-86
pubmed: 15077173
Exp Dermatol. 2004 Jan;13(1):27-32
pubmed: 15009113
Oncotarget. 2012 May;3(5):525-34
pubmed: 22619113
Biomed Pharmacother. 2016 Oct;83:22-32
pubmed: 27470546
Cell Stress Chaperones. 2009 Jan;14(1):105-11
pubmed: 18663603
Int J Mol Sci. 2020 May 26;21(11):
pubmed: 32466509
Head Neck. 1990 May-Jun;12(3):254-6
pubmed: 2358338
Front Oncol. 2019 Sep 10;9:832
pubmed: 31552170
J Cell Physiol. 2017 May;232(5):1086-1094
pubmed: 27487028
Clin Transl Gastroenterol. 2016 Jan 21;7:e138
pubmed: 26795070
Am J Clin Pathol. 2016 Mar;145(3):385-92
pubmed: 27124921
Oncotarget. 2017 Jun 20;8(25):41294-41304
pubmed: 28476040
Oncol Lett. 2013 Apr;5(4):1363-1369
pubmed: 23599795
Chem Biol Interact. 2013 Sep 5;205(1):1-10
pubmed: 23777986
Oncol Rep. 2017 Sep;38(3):1517-1524
pubmed: 28713903
Oncotarget. 2016 Aug 2;7(31):49597-49610
pubmed: 27391062
Clin Cancer Res. 2013 Sep 15;19(18):5016-26
pubmed: 23881928
Cancer Biol Ther. 2009 Oct;8(20):1952-61
pubmed: 19738418
Nature. 2002 Jun 27;417(6892):949-54
pubmed: 12068308
Cancer Biol Ther. 2016 Apr 2;17(4):457-66
pubmed: 26980196
Arch Toxicol. 2013 Jan;87(1):19-48
pubmed: 22885793
Oncogene. 2014 Oct 2;33(40):4867-76
pubmed: 24166505
Sci Adv. 2019 Sep 18;5(9):eaax2277
pubmed: 31555737
Apoptosis. 2011 Jan;16(1):45-54
pubmed: 20862547
Int J Oncol. 2017 Sep;51(3):967-974
pubmed: 28713919
J Exp Clin Cancer Res. 2018 Aug 28;37(1):201
pubmed: 30153855
Dig Dis Sci. 2011 Feb;56(2):323-9
pubmed: 20585984
Mol Imaging Biol. 2016 Aug;18(4):545-56
pubmed: 26604096
Cell Death Discov. 2020 Oct 28;6:112
pubmed: 33133646
Radiat Oncol. 2022 Apr 11;17(1):72
pubmed: 35410422
Mol Cancer Ther. 2017 May;16(5):793-804
pubmed: 28167505
Histopathology. 2019 Aug;75(2):202-212
pubmed: 30882922
Physiol Rev. 2010 Apr;90(2):495-511
pubmed: 20393192
Acta Otorhinolaryngol Ital. 2021 Dec;41(6):514-522
pubmed: 34928263
Cell Prolif. 2009 Apr;42(2):150-61
pubmed: 19317804
Semin Cancer Biol. 2021 Jun 1;:
pubmed: 34087417
Oncotarget. 2013 Nov;4(11):1963-75
pubmed: 24185264
Biol Cell. 2001 Sep;93(1-2):53-62
pubmed: 11730323
Int J Mol Sci. 2019 Sep 11;20(18):
pubmed: 31514477
Invest New Drugs. 2017 Jun;35(3):251-259
pubmed: 28111726
BMC Cancer. 2008 Oct 28;8:312
pubmed: 18957107
Int J Mol Sci. 2018 Aug 29;19(9):
pubmed: 30158430
Angiogenesis. 2013 Oct;16(4):903-17
pubmed: 23838996
Cancer Res. 2005 Jun 1;65(11):4909-17
pubmed: 15930313
Br J Oral Maxillofac Surg. 2017 Apr;55(3):281-286
pubmed: 28209383
Ear Nose Throat J. 2017 Mar;96(3):E13-E16
pubmed: 28346649
Future Oncol. 2013 Mar;9(3):411-8
pubmed: 23469976
Mol Cancer. 2011 Sep 30;10:125
pubmed: 21962244
Anticancer Res. 2014 Aug;34(8):4153-9
pubmed: 25075042
Mol Med. 2021 Oct 19;27(1):130
pubmed: 34666670
Proc Natl Acad Sci U S A. 2006 Jan 3;103(1):57-62
pubmed: 16371460
J Biol Chem. 2002 Jun 7;277(23):20151-9
pubmed: 11916974
J Mol Histol. 2020 Apr;51(2):109-115
pubmed: 32300923
Br J Dermatol. 2017 Aug;177(2):456-469
pubmed: 28078663
Head Neck Pathol. 2017 Mar;11(1):55-67
pubmed: 28247227
Onco Targets Ther. 2018 Apr 11;11:2063-2073
pubmed: 29695914
Mol Cell. 2006 Sep 1;23(5):697-707
pubmed: 16949366
FEBS Open Bio. 2019 Jun;9(6):1119-1127
pubmed: 30985981
Cell Stress Chaperones. 2016 Sep;21(5):927-33
pubmed: 27491302
CA Cancer J Clin. 2017 Jan;67(1):7-30
pubmed: 28055103
J Clin Oncol. 2021 Jun 10;39(17):1909-1941
pubmed: 33900808
Exp Hematol. 2008 Oct;36(10):1266-77
pubmed: 18657349
Int J Cancer. 2009 Dec 15;125(12):2792-801
pubmed: 19544563
Cell Death Dis. 2021 Jan 26;12(1):126
pubmed: 33500390
Arthritis Res Ther. 2008;10(4):212
pubmed: 18771589
Cancer. 2015 Sep 15;121(18):3230-9
pubmed: 26060090
Oral Oncol. 2018 Dec;87:21-28
pubmed: 30527239
Anticancer Res. 2019 Apr;39(4):1767-1775
pubmed: 30952716
Int J Mol Sci. 2022 Mar 03;23(5):
pubmed: 35269948
Sci Rep. 2016 Jan 27;6:19781
pubmed: 26812922
Crit Rev Oncol Hematol. 2010 May;74(2):134-48
pubmed: 19939701
BMC Cancer. 2010 Aug 06;10:409
pubmed: 20691061
J Mol Med (Berl). 2014 Feb;92(2):151-64
pubmed: 24248265
Histopathology. 2010 May;56(6):694-701
pubmed: 20546334